Release Date: February 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: David, what are some of the things you think you can bring to CVS as the new CEO, and can you elaborate on the guidance for 2025? A: David Joyner, President and CEO, emphasized focusing on stabilizing Aetna's operations and financial discipline. He highlighted the transformation in pharmacy pricing models and the success of the biosimilar launch with Cordavis. Joyner expressed confidence in the leadership team and the strategic priorities set for CVS. Regarding guidance, he stressed the importance of establishing trust and credibility, with opportunities for outperformance in 2025.
Q: Can you provide more detail on the Medicare Advantage trend and assumptions for 2025? A: Thomas Cowhey, CFO, noted that medical trends remained elevated but less severe than anticipated. He mentioned modest improvements in Medicare, particularly in group Medicare and dual lines, and some relief on inpatient trends. For 2025, the outlook remains cautious, with trends from 2024 incorporated into the baseline. The focus is on understanding membership mix changes and their impact on performance.
Q: What is the status of Medicare Advantage margins, and what is the expected progression over the next few years? A: Cowhey stated that Medicare Advantage margins ended 2024 in the negative 4.5% to 5% range, with improvements expected in 2025, though not reaching breakeven. Steve Nelson, President of Aetna, highlighted progress in forecasting, pricing discipline, and member experience, expressing confidence in returning to target margins over a multi-year period.
Q: Can you elaborate on the actions taken in the individual ACA business and their expected impact on margins? A: Cowhey explained that the ACA business is expected to shrink significantly in 2025 due to pricing and product mix changes. While improvements are anticipated, the business is not expected to reach breakeven this year. Nelson added that efforts are focused on network design, risk adjustment, and managing total cost of care to return to target margins.
Q: How should we think about the quarterly progression for MLR and the impact of the Inflation Reduction Act? A: Cowhey indicated that earnings would be more weighted to the first half of 2025, with MLRs lowest in the first quarter and higher in the fourth due to changes in Part D premiums and reinsurance protection. The progression of earnings and MLRs will reflect these impacts, with significant swings expected between quarters.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.